Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors (pages 207–216)
Adam S. Levy, Paul A. Meyers, Leonard H. Wexler, Regina Jakacki, Anne Angiolillo, Sarah N. Ringuette, Marvin B. Cohen, Richard Gorlick and Other site principal investigators: Wayne Furman, MD (St. Jude Children's Research Hospital, Memphis, Tennessee); Rochelle Bagatell, MD (University of Arizona Health Sciences Center, Tucson, Arizona); Lori Luchtman-Jones, MD (Washington University School of Medicine, St. Louis, Missouri); Luis Eduardo Garcia, MD (Hospital CIMA, San Jose, Costa Rica); and Eric Sandler, MD (Nemours Children's Clinic, Jacksonville, Florida).
Article first published online: 17 DEC 2008 | DOI: 10.1002/cncr.23992
A recommended phase 2 dose of combination carboplatin and irinotecan was determined for previously treated pediatric patients with recurrent solid tumors. The pharmacokinetics of irinotecan are apparently not affected by concurrent carboplatin.